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Effects of calcitonin and calcium medication in treatment of
edentulous osteoporotic mandible
Efekti primene kalcitonina i kalcijuma u le?enju bezubih pacijenata sa
osteoporoznim mandibulama
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Belgrade, Serbia
Abstract
Background/Aim. In addition to damage of the bones
that support the remaining teeth, degradation of osteopo-
rotic oral bones also lead to a consequent reduction of sup-
porting tissues and the loss of dentures retention. The aim
of this study was to assess the clinical and radiographic out-
comes following injection of a calcitonin and calcium solu-
tion into the buccal aspects of edentulous mandibles.
Methods. The experimental group of 67 edentulous pa-
tients diagnosed with osteoporosis, and the control group of
19 nonosteoporotic edentulous patients were treated with
the  calcitonin and calcium once solution per month. Man-
dibular bone density was measured from panoramic radio-
graphs, supplemented by T scores of skeletal density in the
experimental group. Results. After the therapy, measure-
ments showed moderate increases in bone density, compen-
sating for up to 4% of the total loss of minerals and solidity
of denture-bearing areas of osteoporotic mandibles. Osteo-
porosis affected women earlier than men in this study.
Conclusion. Application of a calcitonin and calcium solu-
tion is a suitable method of preprosthetic therapy for eden-
tulous osteoporotic patients.
Key words:
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Apstrakt
Uvod/Cilj. Degradacija osteoporoznih vili?nih kostiju vodi
ka ošte?enju kostiju koje podržavaju preostale zube, ali i po-
sledi?noj redukciji potpornog tkiva i gubitku retencije prote-
ze. Cilj rada bio je da se procene klini?ki i radiografski pa-
rametri posle tretmana bezubih mandibula rastvorom kal-
citonina i kalcijuma ubrizganog u bukalne recesuse. Meto-
de. Ispitnu grupu ?inilo je 67 bezubih pacijenata sa dijagno-
stikovanom osteoporozom, a kontrolnu grupu 19 bezubih
pacijenata sa normalnom gustinom kosti (bez osteoporoze).
Svi ispitanici dobijali su rastvor kalcitonina i kalcijuma jed-
nom mese?no. Gustina kosti mandibule merena je na osno-
vu ortopantomograma svih ispitivanih pacijenata, uz kom-
plementarni T-nalaz gustine skeleta na sistemskom nivou
kod pacijenata iz ispitne grupe. Rezultati. Po završenoj te-
rapiji utvr?en je umeren porast gustine kosti, ?ime je nado-
kna?eno oko 4% ukupnog gubitka mineralnih supstanci u
regionima nose?eg tkiva osteoporoznih mandibula. Osteo-
poroza je zahvatala kosti žena ranije od kostiju muškaraca u
ovoj studiji. Zaklju?ak. Primena rastvora kalcitonina sa kal-
cijumom predstavlja kvalitetan metod medikacije i prepro-
tetske pripreme bezubih pacijenata obolelih od osteoporoze.
Klju?ne re?i:
osteoporoza; mandibula; bezubost; kalcitonin;
kalcijum; le?enje, ishod.
Introduction
Osteoporotic microstructural degradation and macro-
scopic reduction of the oral bones have been described in the
literature 1. Degradation of osteoporotic oral bones has been
reported not only to damage the bone supporting the re-
maining teeth, but also to lead to a consequent reduction of
supporting tissues and the loss of dentures retention 2. Analy-
sis of the bone layer appearance on panoramic radiographs
was used to assess changes in any parameters of turnover of
jaw bones 3–5.
Calcitonin accelerates influx of calcium, improving
bone mineral content and bone density 6. For this research it
was speculated that these positive effects on osteopenic and
osteoporotic bones could finally be achieved in the mandible,
as well as in other human bones.
Considering various data available on multiple drug
therapy and possible effects of systemic medication, it could
be of particular importance to focus on dependable ap-
proaches to oral treatment of osteoporosis.
The aim of this study was to asses the effectiveness of
local jaw therapy with calcitonin and calcium, used within
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preprosthetic and prosthetic therapy of selected edentulous
osteoporotic patients.
Methods
The study included 67 edentulous patients – 11 men,
aged 64–80 (mean age 71 years) and 56 women, aged 55–79
(mean age 56 years) in the experimental group, and 19
edentulous patients – 9 men, aged 55–65 (mean age 59 year),
and 10 women, aged 40–55 (mean age 53.5 year), with well-
pronounced edentulous ridges and with normal bone density,
as the controls. Edentulous patients were selected based on a
questionnaire concerning previous medical treatments for
osteoporosis, skeletal density, history of fractures of any
bones, postmenopausal periods in women, calcium and mi-
croelements of blood-plasma, as well as oral status of bone
consistency or reduction. No patients had any malignancy or
manifest destructions in the mouth.
Skeletal density analysis was performed on a scanner
(Lunar DPX-L, GE Healthcare, Piscataway, NJ) and T scores
of the patients were obtained, indicating low bone density
and systemic osteoporosis in the experimental group. Scan-
ning was done for at least three of lumbar vertebral bodies in
the regions of L1-L4 lumbar vertebrae of the experimental
group patients. Panoramic radiographs (Orthopantomograph
10-serial no. 01492, Siemens, Germany) of every patient in
the experimental group were focused on degradations in the
osteoporotic jaw (Figure 1a) at baseline. Panoramic radio-
graphic finding of a patient from the control group before
application of calcitonin and calcium solution is shown in
Figure 1b). Calcitonin (Miacalcic, Novartis, Switzerland, and
Huber, Galenika A.D., Serbia), and calcium (Calcium-
gluconate Sterop, Belgium; Calcium-Sandoz, 10% calcium
glubionas amp., Sandoz Switzerland) were used locally to
improve solidity of edentulous mandibles. After local an-
aesthetic application, up to 1.5 mL of a solution containing
calcitonin and calcium (2 : 1 ration in one dose) was injected
submucosally adjacent to the mandibular bone surfaces (Fig-
ure 2). A total of 5 doses were applied to both the right and
left sides of the osteoporotic mandible at monthly intervals,
to each patient of both groups. This treatment was adminis-
tered over a 4-month period. The final separate dose of cal-
citonin and calcium solution was applied only to each patient
of the experimental group at recalls, after 4 months, but not
later than 6 months of follow-up. For the patients of the con-
trol group calcitonin and calcium was applied after tooth ex-
tractions to consolidate the buccal bone and accelerate re-
covery of post-extraction wounds, but also for preventing
bone loss and to compare increments of bone densities be-
tween the control group and the experimental group. Pano-
ramic radiographs of the patients were taken after each ap-
plication of the solution (Figure 3). Complete dentures (CD)
were fabricated for each patient of both groups. All of the
patients had complete dentures during the experimental pe-
riod. During the period of application of the solution con-
taining calcitonin and calcium, a digital densitometer (DT II
05, U.K.) was used to analyse the bone density of mandibu-
a) b)
Fig. 1 – a) A grid positioned in the regions of particular interest for panoramic radiograph of osteoporotic edentulous mandi-
ble and the determined regions – Pr, M1r, M2r, Pl, M1r, M2r (Pr – region of missing premolar to the right side of the mandi-
ble; M1r – region  of missing the 1st molar to the right side of the mandible; M2r – region of missing the 2nd molar to the
right side of the mandible; Pl – region of missing premolar to the left side of the mandible; M1l – region of missing the1st
molar to the left side of the mandible; M2l – region of missing the 2nd molar to the left side of the mandible);
b) – Panoramic radiograph of the control group patient before application of calcitonin and calcium solution.
Fig. 2 – Submucosal injection of a calcitonin and calcium
solution in the buccal aspect of osteoporotic mandible of the
experimental group patient.
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lar segments on panoramic radiographs. Measurements of the
density of the mandibles were taken over the 4 month period
of application of solution. Numerical values of bone density
on radiograph were shown on digital densitometer repre-
senting intensity of entry of focused beam of light into the
determined region of dental panoramic radiographs, and
these values were expressed in arbitrary units of U/mm2.
The Student’s t-test, ANOVA, Pearson’s correlation
coefficient and calculation of the incremental trend were
used for mandibular density analysis.
Results
Before administration of the calcitonin and calcium so-
lution, T-scores from DPX scanning were up to -2.6.for the
men and women of the experimental group.
The results of medication for osteoporotic oral bones
were favourable in this study. The incremental changes in
density of mandibular segments were compared between the
experimental and the control group at each time point, as
well as between the experimental group and the control
group during the therapy.
When mandibular density was compared in the experi-
mental group at baseline and after the 1st month of the ther-
apy, differences were significant for the segments Pr (p <
0.05) with tempo and range of increment of density (R)
1.0080 (0.80%), for Pl (p < 0.05) with R 1.0078 (0.78%), for
M1r (p < 0.05) with R 1.0067 (0.67%), for M1l (p < 0.05)
with R 1.0065 (0.65%), M2r (p < 0.05) with R 1.0062
(0.62%) and M2l (p < 0.05) with R 1.0060 (0.60%). Density
increased further after the 2nd month of application and was
significantly increased for Pr (p < 0.05) with R 1.0087
(0.87%), for Pl (p < 0.05) with R 1.0084 (0.84%), for M1r (p
< 0.05) with R 1.0074 (0.74%), for M1l (p < 0.05) with R
1.0073 (0.73%), M2r (p < 0.05) with R 1.0066 (0.66%) and
M2l (p < 0.05) with R 1.0065 (0.65%). Mandibular density
comparison at baseline and after the 3rd month of application
showed that it was a significant change in density for Pr (p <
0.01) with R 1.0117 (1.17%), for Pl (p < 0.01) with R 1.0114
(1.14%), for M1r (p < 0.01) with R 1.007 (1.07%), for M1l
(p < 0.01) with R 1.0094 (0.94%), M2r (p < 0.05) with R
1.0083 (0.83%) and M2l (p < 0.05) with R 1.0079 (0.79%).
Following application of the calcium and calcitonin
solution, the increase in density was significant for Pr, Pl (p
< 0.01), M1r, M1l, M2r and M2l segments (p < 0.05), with
respect to the baseline (Table 1), compensating for up to 4%
of the total loss of jaw bone mineral in the experimental
group. In the control group, a statistically small increase in
bone density (p < 0.05) was observed in a premolar and the
1st missing molar regions (Table 1).
Discussion
In the dental literature there are few reports on treat-
ment and local medication for osteoporotic oral bones.
Based on convincing medical studies on patients, with
systemic osteoporosis, the two foremost treatment approaches
a)  b)
Fig. 3 – a) Panoramic radiograph of the control group patient after application of calcitonin and calcium solution;
b) – Panoramic radiograph of a patient, exposing a local increment in density edentulous mandible
(for comparisson see Fig. 1).
Table 1
Mandibular bone density in the control and experimental groups at baseline and after administration of calcitonin with
ionized calcium solution
                     Control group                  Experimental group
Digital value of density
? ? SD
Digital value of density
? ? SDSegment
before therapy after therapy       p
Correlation
cofficient before therapy after therapy          p
Correlation
cofficient
Pr 1.01 ? 0.6 1.83 ? 0.7 < 0.05 0.578 -1.42 ? 0.8 0.21 ? 0.7 < 0.01 0.814
Pl 1.03 ? 0.8 1.92 ? 0.4 < 0.05 0.542 -1.40 ? 0.9 0.19 ? 0.6 < 0.01 0.793
M1r 0.83 ? 0.8 1.79 ? 0.8 < 0.05 0.528 -1.34 ? 0.8 -0.24 ? 0.9 < 0.05 0.637
M1l 0.79 ? 0.9 1.76 ? 0.9 < 0.05 0.519 -1.33 ? 0.7 -0.21 ? 0.9 < 0.05 0.619
M2r 1.61 ? 0.5 1.83 ? 0.3 > 0.05 0.394 -1.11 ? 0.9 0.61 ? 0.5 < 0.05 0.593
M2l 1.52 ? 0.8 1.85 ? 0.3 > 0.05 0.367 -1.11 ? 0.4 0.62 ? 0.6 < 0.05 0.607
Numerical values of density are in arbitrary units (U/mm2) showing the intensity of light beam entry through the determined region of dental radiograph.
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could be described: the first related to application of bisphos-
phonates 7, 8, while the second considered calcitonin as the
primary accelerator of calcium influx to the bone 6, 7.
Making an allowance for various facts derived from
studies conducted on patients undergoing systemic therapy
with bisphosphonates, and a few studies on local application
of bisphosphonates, as well as for the fact that certain inter-
ruptions of immune-response were described as a possible
complication of extended bisphosphonate usage 9, therapy
with a solution containing only calcitonin and calcium, ad-
ministered locally to osteoporotic jaws, seemed a rational
option.
Calcitonin has been recognized as the primary sub-
stance that strongly regulates the influx of calcium 6. Cal-
cium influx should have been provided by mobilization of
calcium ions in plasma, as well as by exchanging calcium
ions from pharmacological calcium gluconate and calcium
glubionas. Respecting the fact that human osteoporotic man-
dible may not be very well provided with plentiful blood
supply, it was assumed that calcium ions in blood vessels of
the mandible would not have provided sufficient calcium in-
flux to prevent osteoporotic degradation. Furthermore, addi-
tional sources of calcium ions, directed towards credible lo-
cal storage in close proximity to the mandible, should have a
beneficial effect.
In the dental literature, there were few reports on the lo-
cal application of calcitonin and calcium to hard oral tissues
in vivo.
On the strength of the results of this study, it appears
that the solution of calcitonin and calcium should be applied
to the edentulous ridge prior to positioning of a denture onto
supporting tissues.
Careful selection of patients concerning the absence of
infectious diseases, malignancy, serious kidney problems or
blood diseases, is of ultimate priority when considering local
application of calcitonin and calcium solution to oral bones.
Repeated application of calcitonin and calcium solution
to jaw bone layers may significantly improve the mineral
content of bone, bone density, the condition of the bone and
the potential of the area to support dentures. Osteoporotic
edentulous mandibles should be the first of all oral bones to
benefit from a solution containing calcitonin and calcium.
Additionally, respecting the levels of concentration of cal-
cium ions applied, osteoporotic maxillary bone could be
treated with a solution of the same kind, over a prolonged pe-
riod of remedial use.
A probable contraindication for local oral application of
calcitonin and ionized calcium in solution should be a very
intensive reduction of edentulous ridges with the alveolar
crest positioned under the superficial surface of the mylohy-
oid muscle of the edentulous mouth floor.
Calcitonin accelerated influx of calcium into the man-
dibles of all the patients in both groups.
Since osteoporosis frequently affects women, mandible
osteoporosis is likely to affect women rather than men. The
use of calcitonin and calcium for osteoporotic toothless pa-
tients should be considered the priority for local oral care. In
spite of the limited value of local application, calcitonin and
calcium should be the prerequisite foundation for positive
bone remodelling and turnover of segments of the jaw. Re-
gardless the absence of macroscopically distinct bone regen-
eration, local application of calcitonin with calcium could be
crucial for success at the first point of positive bone remod-
elling and turnover, and for laying the foundation for later
restorative procedures in oral rehabilitation of osteoporotic
patients.
Conclusion
The use of calcitonin and calcium solution should be
considered the priority in preprosthetic and prosthetic ther-
apy of edentulous osteoporotic patients. This medication
compensated for the loss of mineral from the jaw. Applica-
tion of a calcitonin and calcium solution seems to be a suit-
able method of preprosthetic therapy for edentulous osteopo-
rotic patients.
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